Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
Aramark issued a press release on August 11, 2026, announcing third quarter fiscal 2026 financial results for the quarter ended July 3, 2026. The disclosure includes revenue ($5.1 billion, +9% YoY), operating income (+18%), adjusted EPS (+29%), and cash flow metrics, along with updated full-year guidance raising organic revenue growth expectations to +9% to +10%. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 7.01
GrowGeneration published a press release on August 11, 2026 disclosing second quarter 2026 financial results (net sales of $43.2 million, net loss of $2.0 million, positive Adjusted EBITDA of $0.3 million) and updated full-year 2026 guidance (revenue of $162–$168 million, Adjusted EBITDA of $2–$3 million). The filing is Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes consolidated balance sheets and statements of operations for the periods ended June 30, 2026.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99.5
Lithium Argentina announced Q2 2026 financial results with net income of $1.3 million, operating cash flow of $142 million, and adjusted EBITDA of $110 million for the Cauchari-Olaroz operation, along with production of 9,280 tonnes of lithium carbonate and forward-looking guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Keenova Therapeutics plc disclosed its financial results for the second quarter ended June 30, 2026, under Item 2.02, reporting net sales of $517 million from continuing operations, Acthar Gel net sales of $205 million (17% growth), XIAFLEX net sales of $150 million, and a loss from continuing operations of $221 million. The filing includes revised full-year 2026 guidance raising Acthar Gel growth to 20%-22% and tightening XIAFLEX guidance to high single-digits growth, along with pro forma net sales and Adjusted EBITDA guidance. This is a standard quarterly earnings release with material financial results and forward guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 11, 2026. The filing discloses quarterly financial results including R&D expenses ($11.7M), G&A expenses ($4.5M), net loss ($15.2M or $0.12 per share), and cash position ($208.3M), along with clinical development milestones and business highlights. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02, which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
The filing discloses Vestis Corporation's financial results for the fiscal third quarter ended July 3, 2026, including revenue of $661.7 million, net income of $11.0 million, and Adjusted EBITDA of $80.9 million. The company also updated its full-year 2026 outlook, increasing Free Cash Flow guidance by $30 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
C4 Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including revenue ($6.6M), R&D expense ($24.5M), G&A expense ($8.6M), net loss ($23.6M), and cash position ($300.4M). The filing includes condensed consolidated balance sheet and statements of operations data, which are hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99.1
This is a press release announcing ECARX's unaudited financial results for the second quarter ended June 30, 2026. The document discloses Q2 2026 revenue of US$225.2 million (up 45% YoY), gross margin expansion from 10.8% to 19.8%, net loss reduction from US$45.4 million to US$12.0 million, and positive adjusted EBITDA of US$0.5 million. The company also reiterates full-year 2026 guidance of US$1.0–US$1.1 billion in total revenue. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-11
EX-99.5
This is a press release announcing Organigram's third quarter fiscal 2026 financial results, disclosing record quarterly revenue of $145.1 million (gross) and $105.8 million (net), up 49% year-over-year, and adjusted EBITDA of $13.4 million, up 136% year-over-year. The release includes detailed financial statements, balance sheet metrics, and reconciliations of non-IFRS measures. While the exhibit also mentions the departure of CFO Paolo De Luca, the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-11
Item 2.02
The filing discloses Bicara Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes key financial metrics: cash position of $497.3 million (up from $414.8 million at year-end 2025), R&D expenses of $45.8 million (up from $24.8 million YoY), G&A expenses of $14.2 million (up from $7.2 million YoY), and net loss of $55.4 million (up from $27.4 million YoY). While the filing also announces executive leadership transitions, the primary Item 2.02 disclosure centers on quarterly financial results and cash runway guidance through H1 2029, which is material to investor assessment of the company's financial condition and operational trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-11
Item 1.01
Joby Aviation entered into a definitive Stock Purchase Agreement on August 8, 2026, to acquire 100% of Resonant Sciences for approximately $500 million in cash and stock consideration ($450 million cash, $50 million in Joby common stock). The acquisition of this fast-growing defense technology company with $100+ million in trailing-twelve-month revenue materially expands Joby's defense business and is expected to close in H1 2027.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-11
Item 8.01
Joby Aviation entered into an Equity Distribution Agreement (ATM offering) with major investment banks to sell up to $750 million of common stock at the company's discretion, providing capital-raising flexibility for the company.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-11
Item 1.01
Griffon Corporation entered into a Purchase Agreement on August 10, 2026 to issue and sell $800 million aggregate principal amount of 6.25% senior notes due 2034, with net proceeds intended to redeem existing 2028 notes and pay related fees and expenses.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-11
Item 5.02
Alicia Olivo, EVP and General Counsel, is departing her role effective September 21, 2026, with a transition period through October 2, 2026. The disclosure centers on her departure and associated separation payments under her employment agreement. This is a material executive departure affecting the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-11
Item 5.02
The filing discloses the appointment of Vikas Choudhary as a director of Everspin Technologies, effective August 9, 2026. While the disclosure also includes compensatory arrangements (RSU award of $250,000 and annual cash retainer of $55,000), the principal action is the director appointment itself. The detailed biographical information and board service terms confirm this is a material executive appointment that would affect investor assessment of the company's governance and leadership.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99.1
This exhibit is a 2Q26 Earnings Release from KT Corp presenting quarterly financial results including operating revenue (KRW 6,679.9bn), operating income (KRW 648.3bn), net income (KRW 480.6bn), and detailed segment performance across wireless, fixed-line, B2B services, and major subsidiaries. The document explicitly states "2Q26 Earnings Release" in the header and contains comprehensive financial highlights, income statements, balance sheets, and operational metrics typical of a quarterly results announcement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-11
EX-99.1
This exhibit is a comprehensive corporate strategy presentation disclosing KT Corp's "Corporate Value-Up Plan," which outlines multi-year operational and financial targets including AX (AI Transformation) expansion, profitability enhancement, asset optimization, and shareholder returns through 2028. While it includes financial metrics and ROE targets (9–10% by 2028), it is fundamentally a strategic business plan and operational roadmap rather than a discrete financial event, earnings release, or periodic report. The disclosure addresses business transformation, capital allocation strategy, and governance improvements—all operational and strategic in nature.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-11
EX-99.1
AC Immune announced FDA Fast Track designation and IND clearance for ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. This is a material regulatory milestone enabling expansion of the Phase 2 VacSYn trial to U.S. sites, supported by positive interim safety and immunogenicity data. While not a discrete M&A, financing, or executive event, this regulatory achievement materially advances the company's clinical development program and would affect a reasonable investor's assessment of pipeline progress and regulatory pathway.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-08-11
This is a half-year financial report for the six months ended 30 June 2026, furnished as Exhibit 99.1 to the Form 6-K. The document presents interim financial statements, operating metrics, and management discussion covering H1 2026 results, system size and pipeline progress, and strategic priorities. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-11
Item 8.01
Beyond Meat announced a 1-for-30 reverse stock split explicitly "intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market." The disclosure directly addresses delisting risk and the remedial action taken to address it. While the reverse split itself is a capital structure event, the material disclosure here centers on the company's failure to meet Nasdaq listing standards and the corrective measure, which is the hallmark of delisting_risk classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Absci Corporation announced Q2 2026 financial results (revenue $0.3M, R&D expenses $22.6M, SG&A expenses $9.2M, net loss $33.2M, cash $201.1M) via press release on August 11, 2026, along with clinical trial updates including positive Phase 1 interim data from the HEADLINE trial of ABS-201 and a $100 million capital raise including a $40 million strategic investment from Eli Lilly.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-11
Item 7.01
Unusual Machines disclosed a definitive agreement to acquire Upgrade Energy to strengthen domestic battery capabilities, along with aggressive inventory and production expansion plans and positioning around regulatory tailwinds including NDAA, FCC Secure Networks Act, and Drone Dominance Program. The disclosure was made via an updated investor presentation (Exhibit 99.1) dated August 10, 2026, furnished under Regulation FD.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-11
EX-99.1
This is a news release dated August 11, 2026, announcing BioHarvest's second quarter 2026 financial results. The exhibit discloses Q2 2026 revenues of $8.8 million (up 3.8% YoY), net loss of $3.7 million, and six-month results, along with revised full-year 2026 guidance. The document includes detailed financial statements (balance sheet, income statement, changes in equity) and is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-11
Item 2.02
Autolus Therapeutics disclosed Q2 2026 financial results on August 11, 2026, reporting net product revenue of $45.7 million (up 119% year-over-year), gross margin improvement to 55%, an operating loss of $43.8 million, and a net loss of $39.1 million. The company also provided updated full-year 2026 revenue guidance of $140–$150 million and discussed operational updates including a debt facility and workforce reduction.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99.1
Legend Biotech disclosed Q2 2026 unaudited financial results including revenue of $387.5 million and net income of $33.2 million, along with consolidated financial statements for the three and six months ended June 30, 2026 and management commentary on business performance and clinical milestones.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-11
Item 5.02
Dr. Erica Schwartz resigned as a director of Butterfly Network effective August 5, 2026, upon her confirmation as Director of the Centers for Disease Control and Prevention. The filing explicitly states her resignation was "automatically effective upon such confirmation" and emphasizes it was not due to any disagreement with the Company. This is a clear director departure, material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
LENZ Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026. The disclosure includes Q2 2026 total revenue of $5.5 million (product sales of $1.7 million and license revenue of $3.8 million), net loss of $31.9 million for the quarter, and detailed operating metrics. The press release is attached as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings releases. This is material to investors as it reports the company's first full quarter of commercial product sales following VIZZ's FDA approval in July 2025.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Veradermics issued a press release on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $23.5 million, R&D expenses of $18.6 million, G&A expenses of $10.9 million, and cash position of $819.9 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational highlights regarding clinical trial progress for VDPHL01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-11
The filing discloses Item 5.07 results from Nexalin Technology's annual stockholder meeting held August 11, 2026, including voting outcomes on six proposals: election of five directors (all passed), approval of the 2026 Equity Incentive Plan (passed), reverse stock split authorization (passed), preferred stock authorization (failed), officer exculpation amendment (failed), and auditor ratification (passed). This is a standard shareholder vote results disclosure with material governance implications.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-11
Item 2.02
Janus International Group issued a press release on August 11, 2026 announcing financial results for the quarter ended July 4, 2026, with revenues of $233.5 million (up 2.4% YoY), net income of $10.7 million ($0.08 per diluted share), and Adjusted EBITDA of $40.2 million (down 18.0% YoY), along with updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Zura Bio issued a press release on August 11, 2026 announcing its second quarter 2026 financial results, including consolidated balance sheets, statements of operations, and key financial metrics (cash position of $205.1 million, R&D expenses of $20.7 million, net loss of $26.3 million), along with material clinical program updates including completion of enrollment in TibuSHIELD and TibuSURE trials and initiation of the NEXUS-PMR study.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99.3
This is a press release announcing On Holding AG's financial results for Q2 2026 and the six-month period ended June 30, 2026. The document discloses detailed quarterly and interim financial metrics including net sales (CHF 850.3 million, up 13.5% YoY), gross profit margin (65.4%, up 3.9 percentage points), adjusted EBITDA (CHF 168.1 million), net income (CHF 105.0 million), and EPS figures, along with forward guidance for full-year 2026. This is a classic earnings release event material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-11
Item 7.01
Barings Private Credit Corporation sold approximately $101.5 million of common stock pursuant to subscription agreements with investors, exempt from Securities Act registration under Section 4(a)(2) and Regulation D/S. This is a material unregistered equity issuance that will dilute existing shareholders, fitting the dilutive_issuance category. The magnitude ($101.5M) and the explicit exemption from registration requirements are hallmarks of this event type.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-08-11
EX-99.1
The exhibit is a press release announcing a Board-approved cash distribution of US$0.22 per share for June 2026, with record date August 21, 2026 and payment date on or about August 27, 2026. The disclosure includes detailed distribution mechanics, currency information, and ex-dividend dates for both Euronext and NYSE listings. This is a material dividend distribution event requiring disclosure under standard securities regulations.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-11
EX-99.1
Himalaya Shipping Ltd. announced preliminary unaudited financial results for Q2 2026 and the six-month period ended June 30, 2026, reporting net income of $24.6 million for Q2 2026 (vs. $1.1 million in Q2 2025) and $29.6 million for H1 2026 (vs. a loss of $5.3 million in H1 2025), with detailed consolidated financial statements and a results presentation disclosing EBITDA of $44.0 million, TCE earnings of $50,600/day, and cash distributions of $0.59 per share.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-11
Cadeler announces the completion of a strategic acquisition of Menck, a leading offshore foundation installation equipment provider, for an enterprise valuation of EUR 501 million. The filing explicitly states "signing and closing completed simultaneously" and describes this as a "step-change in the development of Cadeler's offshore foundation transportation and installation," financed through a EUR 380 million acquisition facility. This is a material M&A transaction that materially expands Cadeler's capabilities and is expected to impact 2026 revenue and EBITDA guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
Venture Global issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including revenue of $4.6 billion (up 48% YoY), net income of $1.3 billion (up 266% YoY), and Consolidated Adjusted EBITDA of $2.5 billion (up 79% YoY). The press release is furnished as Exhibit 99.1 and includes detailed financial tables, operational highlights, and updated 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Enviri Corporation issued a press release on August 11, 2026 announcing its second quarter 2026 earnings results, including revenues of $187 million (GAAP) and $324 million (adjusted), GAAP diluted loss per share of $10.70, and Adjusted EBITDA of $34 million. The disclosure is a standard quarterly earnings announcement with detailed segment results, cash flow metrics, and forward guidance, filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Alico issued a press release on August 10, 2026 announcing financial results for the three and nine months ended June 30, 2026, disclosing net income of $2.1 million and $10.0 million respectively, along with Adjusted EBITDA, cash position, and updated fiscal year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
BRT Apartments Corp. disclosed quarterly financial results for the three and six months ended June 30, 2026, including net loss per diluted share of $0.19 (vs. $0.14 in Q2 2025), FFO and AFFO metrics, and detailed operating results with revenue and expense breakdowns.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-10
Item 8.01
The disclosure describes a material acquisition transaction: Patrick Industries entered into a Merger Agreement on June 30, 2026 to acquire LCI Industries through a two-step merger structure. The filing updates on HSR Act compliance filed August 5, 2026, which is a key closing condition. This is a material M&A activity requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 as a progress update on a previously announced transaction.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-10
Item 2.03
PECO Energy issued $750 million in First and Refunding Mortgage Bonds at 5.000% due 2031 on August 10, 2026, pursuant to a supplemental indenture dated July 15, 2026. The bonds are payable semi-annually and redeemable at the company's option, creating a significant new direct financial obligation.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-10
Item 5.02
Mr. Gary S. Gladstein notified the Board on August 6, 2026 that he will retire from the Board effective December 31, 2026, ending his 30 years of combined service including roles as Chairman (2013–2015) and Lead Independent Director (2016–2018).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-10
Item 8.01
Mueller Industries' Board declared a regular quarterly cash dividend of 17.5 cents per share, payable September 18, 2026 to shareholders of record on September 4, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
SIFCO Industries issued a press release on August 10, 2026 announcing financial results for its third quarter and nine months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date net sales, net income/loss from continuing operations, EBITDA, and Adjusted EBITDA metrics, along with consolidated financial statements. This is a standard earnings release disclosure under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-10
Item 5.02
Southwest Airlines appointed two new directors to its Board: Varun Krishna (CEO of Rocket Companies and interim CEO of Redfin) and Jason T. Liberty (Chair and CEO of Royal Caribbean Cruises Ltd.), effective immediately, increasing the Board size to thirteen members.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Team, Inc. disseminated a press release on August 10, 2026, announcing unaudited financial results for the second quarter ended June 30, 2026. The disclosure includes Q2 2026 revenue ($228.7M vs. $248.0M prior year), net loss ($6.8M vs. $4.3M prior year), Adjusted EBITDA ($12.8M vs. $24.5M prior year), segment results, balance sheet metrics, and full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Telos Corporation issued a press release on August 10, 2026, announcing its second quarter 2026 financial results, including revenue of $47.7 million (33% YoY growth), GAAP net income of $0.7 million, and Adjusted EBITDA of $6.9 million. The company also raised its full-year profit guidance. This is a standard quarterly earnings release disclosure under Item 2.02, with exhibits 99.1 and 99.2 containing the press release and detailed financial results.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-10
Item 5.02
Johanna Nielsen's resignation as Vice Vice President, Chief Accounting Officer and Corporate Controller, effective September 4, 2026, is the principal disclosed action. While the filing also mentions David Denton assuming the interim role, the core event is Nielsen's departure from a senior accounting position. The departure of a Chief Accounting Officer is material to investors as it affects financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
L.B. Foster Company issued a press release on August 10, 2026 announcing second quarter 2026 results of operations for the period ended June 30, 2026. The disclosure includes detailed financial metrics (net sales, gross profit, operating income, net income, Adjusted EBITDA, cash flow), segment performance, and full-year 2026 financial guidance reaffirmation. This is a standard quarterly earnings release attached as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →